January 4, 2018 / 12:40 PM / in 20 days

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

Jan 4 (Reuters) - Rigel Pharmaceuticals Inc:

* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​

* RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below